Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
-
Patent number: 9345771Abstract: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.Type: GrantFiled: October 4, 2012Date of Patent: May 24, 2016Assignee: INSYS DEVELOPMENT COMPANY, INC.Inventors: Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill
-
Patent number: 9271977Abstract: There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.Type: GrantFiled: December 20, 2011Date of Patent: March 1, 2016Assignee: NeuroVive Pharmaceutical ABInventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Steven Gary Kendrew, Christine Janet Martin
-
Patent number: 9259449Abstract: A method for modifying THC content in a lipid-based extract of cannabis to yield a low-THC product. The method includes providing a lipid-based extract of cannabis containing THC, heating the lipid-based extract at 1 atm of pressure to 157 to 160° C. to vaporize a first portion of the THC, and converting a second portion of the THC to CBN by heating the lipid-based extract to between 130° C.-150° C. for at least 10 min.Type: GrantFiled: December 31, 2014Date of Patent: February 16, 2016Inventor: Joshua Michael Raderman
-
Patent number: 9066920Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.Type: GrantFiled: June 29, 2010Date of Patent: June 30, 2015Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., LimitedInventors: Ben Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
-
Publication number: 20150141501Abstract: This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.Type: ApplicationFiled: November 18, 2014Publication date: May 21, 2015Inventor: Mark Tepper
-
Publication number: 20150140076Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: ApplicationFiled: January 30, 2015Publication date: May 21, 2015Applicant: SARCODE BIOSCIENCE INC.Inventors: Thomas Gadek, John Burnier
-
Publication number: 20150132400Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.Type: ApplicationFiled: May 3, 2013Publication date: May 14, 2015Applicant: Echo Pharmaceuticals B.V.Inventors: Jan Albert De Vries, Maria Vanesa Fernandez Cid, Ana Maria Heredia Lopez
-
Publication number: 20150126595Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.Type: ApplicationFiled: December 4, 2014Publication date: May 7, 2015Inventor: Nicole SMITH
-
Publication number: 20150126596Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinoI and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.Type: ApplicationFiled: January 13, 2015Publication date: May 7, 2015Inventors: Arie L. GUTMAN, Marina ETINGER, Irina FEDOTEV, Ram KHANOLKAR, Gennady A. NISNEVICH, Boris PERTSIKOV, Igor RUKHMAN, Boris TISHIN
-
Publication number: 20150118301Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: September 4, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150119788Abstract: The present disclosure provides biophotonic topical compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure are substantially resistant to leaching such that very low amounts of chromophore(s) present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various skin disorders.Type: ApplicationFiled: April 19, 2013Publication date: April 30, 2015Inventors: Nikolaos Loupis, Remigio Piergallini, Shipra Rastogi
-
Publication number: 20150119456Abstract: The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: ApplicationFiled: January 17, 2013Publication date: April 30, 2015Inventors: Thomas D. Pallin, Hazel J. Dyke, Susan M. Cramp, Robert Zahler
-
Publication number: 20150119424Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of convulsions, Lennox-Gastaut syndrome, migraine, bipolar disorder, post traumatic stress disorder.Type: ApplicationFiled: August 16, 2013Publication date: April 30, 2015Inventor: Mahesh KANDULA
-
Patent number: 9012494Abstract: The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; L represents a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydroxy-C1-4alkyl, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from hydroxy, C1-4alkyl or C1-4alkyloxy; R1 and R2 each independently represent hydrogen, halo, cyano, hydroxy, C1-4alkyl optionally substituted with halo, C1-4alkyloxy- optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar1 and halo; or R1 and R2 taken together with the phenyl ring to which they are attached form naphtyl or 1,3-benzodioxolyl, wherein said naphtyl or 1,3-benzodioxolyl are optionally substituted with halo; R3 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R4 represents hydrogen, halo,Type: GrantFiled: April 29, 2005Date of Patent: April 21, 2015Assignee: Janssen Pharmaceutica N.V.Inventors: Libuse Jaroskova, Joannes Theodorus Maria Linders, Christophe Francis Robert Nestor Buyck, Louis Jozef Elisabeth Van Der Veken, Vladimir Dimtchev Dimitrov, Theo Teofanov Nikiforov
-
Publication number: 20150104387Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: April 2, 2014Publication date: April 16, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
-
Publication number: 20150105455Abstract: The present technology relates to liquid compositions for use in a personal vaporizer. More particularly, the present technology relates to liquid compositions comprising winterized Cannabis extract, and to methods of administering vaporized winterized Cannabis extract to a subject by inhalation.Type: ApplicationFiled: March 25, 2014Publication date: April 16, 2015Inventor: William Bjorncrantz
-
Topiramate Sustained-Release Pharmaceutical Composition, Method for Preparing Same, and Uses Thereof
Publication number: 20150099003Abstract: A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.Type: ApplicationFiled: March 7, 2013Publication date: April 9, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang -
Patent number: 8992989Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: GrantFiled: September 29, 2014Date of Patent: March 31, 2015Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Publication number: 20150086494Abstract: A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.Type: ApplicationFiled: September 26, 2014Publication date: March 26, 2015Inventors: Ronald D. SEKURA, Roscoe M. Moore, JR.
-
Publication number: 20150087620Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.Type: ApplicationFiled: April 23, 2013Publication date: March 26, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
-
Patent number: 8980942Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.Type: GrantFiled: July 23, 2012Date of Patent: March 17, 2015Assignee: Zynerba Pharmaceuticals, Inc.Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
-
Patent number: 8980941Abstract: The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (?9-THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small amount of the cofactor and only some of the medicinal cannabis contained in raw cannabis will be converted from an acidic form into a non-acidic form. Use a large amount of the cofactor and most or all of the medicinal cannabis will be decarboxylated. The reaction is proportional to the molar mass of cofactor.Type: GrantFiled: August 19, 2011Date of Patent: March 17, 2015Inventor: Andrew David Hospodor
-
Patent number: 8980940Abstract: A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.Type: GrantFiled: November 22, 2011Date of Patent: March 17, 2015Assignee: Johnson Matthey Public Limited CompanyInventors: Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
-
Publication number: 20150072020Abstract: There is described a method of treating cancer in a patient wherein the method comprises the administration of dexanabinol, or a derivative thereof, in an amount of from about 2 mg/kg to about 30 mg/kg, based on the weight of the patient.Type: ApplicationFiled: April 26, 2013Publication date: March 12, 2015Applicant: E-THERAUPEUTICS PLCInventors: Malcolm Philip Young, Philip McKeown
-
Patent number: 8974363Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.Type: GrantFiled: November 8, 2007Date of Patent: March 10, 2015Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher
-
Patent number: 8969406Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:Type: GrantFiled: March 18, 2013Date of Patent: March 3, 2015Assignee: China Medical UniversityInventors: Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang, Da-Wei Chuang, Juan-Cheng Yang
-
Publication number: 20150056292Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.Type: ApplicationFiled: March 22, 2013Publication date: February 26, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Sciences P.L.A. ChinaInventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
-
Publication number: 20150057342Abstract: Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof.Type: ApplicationFiled: July 31, 2014Publication date: February 26, 2015Inventors: Zohar KOREN, Eyal BALLAN, Itamar BOROCHOV, Shay Avraham SARID
-
Publication number: 20150057153Abstract: This invention relates to compositions and methods for improving water quality by enhancing natural bacterial processes and altering environmental conditions in situ. This is achieved by the manufacture and use of granules or tables composed of the inventive formulations.Type: ApplicationFiled: June 24, 2014Publication date: February 26, 2015Inventor: John W. DiTuro
-
Publication number: 20150057237Abstract: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.Type: ApplicationFiled: October 29, 2014Publication date: February 26, 2015Applicant: SupraPolix B.V.Inventors: Patricia Yvonne Wilhelmina DANKERS, Gaby Maria Leonarda HOORNE-VAN GEMERT, Henricus Marie JANSSEN, Egbert Willem MEIJER, Anton Willem BOSMAN
-
Publication number: 20150057341Abstract: A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.Type: ApplicationFiled: August 22, 2013Publication date: February 26, 2015Inventor: Stephen C. Perry
-
Publication number: 20150045282Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.Type: ApplicationFiled: August 18, 2014Publication date: February 12, 2015Inventors: Mahmoud A. ELSOHLY, Waseem GUL, Michael A. REPKA, Soumyajit MAJUMDAR, Mohammad Khalid ASHFAQ
-
Publication number: 20150038567Abstract: The invention relates to a compound selected from the group consisting of all stereoisomers and their mixtures of the compounds of general formulas (1)-(4), in which R1 is a straight-chained, branched or cyclic hydrocarbon group with up to 12 C-atoms and X+ is selected from the group consisting of H+, NH4+, mono, di or trivalent metal cations, NH4+, primary, secondary, tertiary or quaternary organic ammonium ions with up to 48 C-atoms, which can carry even more functional groups, hydrazinium ion (N2H5+), hydroxylammonium ion (NH3OH+), guanidinium ion (CN3H6+), and organic derivatives of (N2H5+), NH3OH+, and CN3H6+, which can carry even more functional groups, and similar.Type: ApplicationFiled: October 1, 2012Publication date: February 5, 2015Applicant: THE HEALTH CONCEPT GMBHInventors: Thomas Herkenroth, Christian Steup
-
Publication number: 20150025043Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.Type: ApplicationFiled: June 4, 2012Publication date: January 22, 2015Applicant: Mitotech SAInventors: Maxim V. Skulachev, Vladimir P. Skulachev, Andrey A. Zamyatnin, Vadim N. Tashlitsky, Roman A. Zinovkin, Maxim V. Egorov, Lawrence T. Friedhoff, Olga Y. Pletushkina, Alexander A. Andreev-Andrievsky, Tatiana V. Zinevich
-
Patent number: 8937097Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.Type: GrantFiled: February 22, 2013Date of Patent: January 20, 2015Assignee: Purdue Pharma L.P.Inventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
-
Publication number: 20150017249Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: ApplicationFiled: September 29, 2014Publication date: January 15, 2015Applicant: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua WANG, Padmanabh P. BHATT, Michael L. VIEIRA
-
Patent number: 8933116Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.Type: GrantFiled: April 4, 2012Date of Patent: January 13, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee
-
Publication number: 20150010626Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: ApplicationFiled: September 24, 2014Publication date: January 8, 2015Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8927594Abstract: The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2.Type: GrantFiled: March 15, 2011Date of Patent: January 6, 2015Assignees: National Sun Yat-Sen University, National Museum of Marine Biology & AquariumInventors: Jyh-Horng Sheu, Wei-Hsien Wang, Zhi-Hong Wen, Bo-Wei Chen, Ping-Jyun Sung
-
Publication number: 20150005292Abstract: There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Applicant: CHASE PHARMACEUTICALS CORPORATIONInventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
-
Publication number: 20150004626Abstract: The present invention relates to a method for labeling or targeting cells whose plasma membrane has lost integrity, such as dead cells, such as for discriminating between live cells and cells whose plasma membrane has lost integrity; to an embodiment of the method for determining one or more values of one or more parameters of cells of a biological sample; to use of the method in an assay for screening drugs for therapy such as cancer therapy; to use of the method to monitor and/or determine the effectiveness of a therapy; to an assay kit; to a complex; to the complex for use as a medicament; to the complex for use in treatment of cancer(s) and/or plaque(s) and/or regeneration and/or supporting the immune system; and, to a dead cell.Type: ApplicationFiled: February 6, 2013Publication date: January 1, 2015Inventors: Markwin Hendrik Maring, Clemens Waltherus Gerardus Löwik, Ermond Reijer Van Beek
-
Publication number: 20150004205Abstract: The invention generally relates to surfaces having a protein-resistant hydrogel layer and methods for preparing a protein-resistant hydrogel layer on a surface. The protein-resistant hydrogel layer is formed by a protein-crosslinked water soluble polymer that is contacted with a surface to form a thin protein-resistant hydrogel layer on the surface.Type: ApplicationFiled: June 18, 2014Publication date: January 1, 2015Inventors: Donald Elbert, Megan Kaneda, Evan Scott, Brad Wacker
-
Publication number: 20140378539Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: December 25, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Patent number: 8906416Abstract: The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a C1-C24 alkyl radical a C12-C24 alkenyl radical comprising at least one unsaturation; R4 represents: COR5, a glucide substituted or not by one or more acetyl radical(s); R5 represents: a C10-C24 alkyl radical or a C12-C24 alkenyl radical comprising at least one unsaturation; R6 and R7 represent:—simultaneously a hydrogen atom or a methyl radical, or—when R6 represents a hydrogen atom, R7 represents a C1-C6 alkyl radical or a phenyl substituted or not by one or more C1-C3 alkoxy radical(s) or one or more halogen(s) or—R6 and R7 are bonded together and form a C3-C6 cycloalkyl, and pharmaceutically or cosmetically acceptable salts.Type: GrantFiled: July 8, 2011Date of Patent: December 9, 2014Assignee: Pierre Fabre Dermo-CosmetiqueInventors: Stéphane Poigny, Françoise Belaubre
-
Patent number: 8906956Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.Type: GrantFiled: June 7, 2013Date of Patent: December 9, 2014Assignee: Johnson Matthey Public Limited CompanyInventors: Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
-
Publication number: 20140357708Abstract: An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) about 15 to 85 wt % of one or more triglycerides formed from long chain fatty having from C13 to C24 carbon atoms; (ii) about 15 to 85 wt % of one or more mixed glycerides formed from long chain fatty having from C13 to C24 carbon atoms; and (iii) one or more free fatty acids formed from un-esterified long chain fatty acids having from C13 to C24 carbon atoms; and (c) about 10 to 70 wt % of a surfactant which promotes self-emulsification.Type: ApplicationFiled: August 7, 2014Publication date: December 4, 2014Inventors: Santos B. Murty, Ram B. Murty
-
Publication number: 20140357586Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventor: Mahesh V. Patel
-
Publication number: 20140348931Abstract: The present invention relates to a sustained release pharmaceutical formulation comprising topiramate and one or more pharmaceutically acceptable excipients, wherein the formulation comprises two extended release (XR) components or a combination of an extended release (XR) component and immediate release (IR) component, wherein at least one component is in a matrix form. It also relates to method of preparing such formulations and using those formulations in the treatment of neurological and/or psychiatric condition.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Applicant: CADILA HEALTHCARE LIMITEDInventors: SUSHRUT KRISHNAJI KULKARNI, AJAYKUMAR HANDA, AMIT OM PRAKASH GUPTA, PRUDHVI RAJU DANTULURI
-
Publication number: 20140343136Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.Type: ApplicationFiled: November 21, 2012Publication date: November 20, 2014Inventors: Angelo Antonio Izzo, Francesca Borelli, Stephen Wright
-
Publication number: 20140335208Abstract: The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.Type: ApplicationFiled: November 20, 2012Publication date: November 13, 2014Inventors: Michael Cawthorne, Colin Stott, Stephen Wright